Christian Oliver, MD
Interventional Pain Medicine · Bridgeton, MONPI 1316387327
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $14,738 of the $17,960 with a category attached, or 82.1%. 32 manufacturers reported payments, led by Nevro Corp. at 27.8% of the total. Reporting peaked in 2022 at $4,518 and has fallen 64.1% since, to $1,622 in 2025.
Across 308 payments — averaging $58.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Nevro Corp.$5K
- Medtronic$3K
- Abbott$2K
- Boston Scientific$2K
- Spinal Simplicity, LLC$1K
- Globus Medical$898
- plus $3K from 26 others
What the payments were for
- Travel & lodging$2,90216%
- Food & beverage$14,73882%
- Entertainment$3202%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Nevro Corp. | 54 | $4,996 |
| Medtronic(2 entities) | 36 | $3,128 |
| Abbott | 59 | $2,324 |
| Boston Scientific | 26 | $2,253 |
| Spinal Simplicity, LLC | 12 | $1,256 |
| Globus Medical | 11 | $898 |
| Vertos Medical, Inc. | 9 | $841 |
| Corelink, LLC | 5 | $332 |
| Zavation Medical Products, LLC | 1 | $320 |
| Biodelivery Sciences International, Inc. | 11 | $211 |
| Zyla Life Sciences, Inc. | 22 | $184 |
| Sentynl Therapeutics, Inc. | 14 | $160 |
| Nalu Medical, Inc. | 1 | $135 |
| Saluda Medical Americas, Inc. | 1 | $127 |
| Collegium Pharmaceutical, Inc. | 9 | $117 |
| Painteq LLC | 1 | $113 |
| Amgen | 7 | $111 |
| Scilex Pharmaceuticals Inc. | 6 | $100 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $70 |
| Pfizer | 5 | $62 |
| Kaleo, Inc. | 3 | $39 |
| Stryker | 2 | $27 |
| Si-bone, Inc. | 1 | $26 |
| Redhill Biopharma Inc. | 1 | $21 |
| Biotronik NRO, Inc. | 1 | $20 |
| Curonix LLC | 1 | $19 |
| Averitas Pharma Inc. | 1 | $16 |
| Bioventus LLC | 1 | $13 |
| Pacira Therapeutics, Inc. | 1 | $13 |
| Daiichi Sankyo Inc. | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
| Assertio Therapeutics, Inc. | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Senza$2,979
- Omnia$1,589
- SYNCHROMEDII$1,223
- HA MINUTEMAN G3-R$1,113
- SUPERION$772
- mild Device Kit$575
- Axium INS DRG IPG$538
- INTELLIS ADAPTIVESTIM$410
- INCEPTIV$311
- SPECTRA WAVEWRITER$264
- Proclaim Family of SCS IPGs$258
- Proclaim IPG$252
- Senza Spinal Cord Stimulation System$203
- Nalu Neurostimulation System$135
- Evoke$127
- BELBUCA$116
- PAINTEQ$113
- VANTA ADAPTIVESTIM$110
- PROCLAIM$109
- GENERAL - THERAPIES$107
How this compares
$17,960 in reported general payments places this provider in the 85th percentile of 27 interventional pain medicine providers in Missouri.
See all interventional pain medicine providers in Missouri →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BelbucaBuprenorphine Hcl | 26 | $22,366 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 734 | $16,658 |
| MovantikNaloxegol Oxalate | 19 | $16,290 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 681 | $15,094 |
| Pregabalin | 366 | $12,688 |
| Gabapentin | 413 | $6,059 |
| Tizanidine Hcl | 307 | $4,201 |
| Tramadol Hcl | 143 | $2,633 |
| Naloxone Hcl | 35 | $2,195 |
| Lidocaine | 20 | $2,100 |
| Celecoxib | 92 | $2,050 |
| Baclofen | 86 | $1,642 |
| Fluticasone Propionate | 14 | $1,579 |
| Oxycodone Hcl | 72 | $1,129 |
| Duloxetine Hcl | 65 | $1,113 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca | $117 | $22,36626 claims |
| Redhill Biopharma Inc.Movantik | $21 | $16,29019 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 27 interventional pain medicine providers in Missouri.
Other interventional pain medicine in Bridgeton
- Ramis GheithBridgeton$73K
- Rebecca SandersJoplin$209K
- Helen BlakeChesterfield$48K
- Andrew FrazierKansas City$32K
- David TonkinSpringfield$14K
- Dwayne JonesKansas City$11K
- Bradford NobleColumbia$8K
- Calvin CajigalDes Peres$8K
- James NewtonColumbia$7K
- Ihab DossWarrensburg$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.